Novel histamine H3-receptor antagonists with benzyl ether structure or related moieties: Synthesis and structure-activity relationships

Archiv der Pharmazie

Volumn 329, Issue 8-9, 1996, Pages 379-385

  Hüls, Annette ^a   Purand, Katja ^a   Stark, Holger ^a   Reidemeister, Sibylle ^a   Ligneau, Xavier ^b   Arrang, Jean Michel ^c   Schwartz, Jean Charles ^c   Schunack, Walter ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b Laboratoire Bioprojet   (France)

^c CENTRE PAUL BROCA   (France)

Author keywords

3 (1H imidazol 4 yl)propyl ether; antagonist; H3 receptor; histamine

Indexed keywords

3 (1H IMIDAZOL 4 YL)PROPYL 1 NAPHTHYLMETHYL ETHER; ETHER DERIVATIVE; HISTAMINE H3 RECEPTOR; HISTAMINE H3 RECEPTOR ANTAGONIST; IODOPROXYFAN; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG; ANTIHISTAMINIC AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; GUINEA PIG; HISTAMINE RELEASE; ILEUM; IN VITRO STUDY; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION; SYNAPTOSOME; ANIMAL; DRUG EFFECT; SYNTHESIS;

ANIMALS; CEREBRAL CORTEX; GUINEA PIGS; HISTAMINE ANTAGONISTS; ILEUM; MICE; RATS; RECEPTORS, HISTAMINE H3; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0029661861     PISSN: 03656233     EISSN: None     Source Type: Journal    
DOI: 10.1002/ardp.19963290802     Document Type: Article

References (36)

1. J.-M. Arrang, M. Garbarg, J.-C. Schwartz, Nature (London) 1983, 302, 832-837.
2. J.-M. Arrang, M. Garbarg, J.-C. Schwartz, Neuroscience 1985, 15, 553-562.
3. J.-M. Arrang, M. Garbarg, J.-C. Schwartz, Neuroscience 1987, 23, 149-157.
4. E. Schlicker, R. Betz, M. Göthert, Naunyn-Schmiedebergs Arch. Pharmacol. 1988, 337, 588-590.
5. J. Clapham, G. J. Kilpatrick, Br. J. Pharmacol. 1992, 107, 919-923.
6. K. Fink, E. Schlicker, M. Göthert, Adv. Biosci. 1991, 82, 125-126.
7. E. Schlicker, W. Schunack, M. Göthert, Naunyn Schmiedebergs Arch. Pharmacol. 1990, 342, 497-501.
8. E. Schlicker, K. Fink, M. Detzner, M. Göthert, J. Neural. Transm. [Gen. Sect] 1993, 93, 1-10.
9. S. Taylor, G. Kilpatrick, Br. J. Pharmacol. 1992, 105, 667-674.
10. J.-M. Arrang, M. Garbarg, J.-C. Lancelot, J.-M. Lecomte, H. Pollard, M. Robba, W. Schunack, J.-C. Schwartz, Nature (London) 1987, 327, 117-123.
11. H. Yokoyama, K. Onodera, K. Iinuma, T. Watanabe, J. Pharmacol. 1993, 234, 129-133.
12. P. Soe-Jensen, U. Knigge, M. Garbarg, A. Kjaer, A. Rouleau, F. W. Bach, J.-C. Schwartz, J. Warberg, Neuroendocrinology 1993, 57, 532-540.
13. K.-I. Meguro, K. Yanai, N. Sakai, E. Sakurai, K. Maeyama, H. Sasaki, T. Watanabe, Pharmacol. Biochem. Behav. 1995, 50, 321-325.
14. J. M. Monti, Life Sci. 1993, 53, 1331-1338.
15. J. W. Black, W. A. M. Duncan, J. C. Emmett, C. R. Ganellin, T. Hesselbo, M. E. Parsons, Agents Actions 1994, 43, 91-96.
16. J.-C. Schwartz, J.-M. Arrang, M. Garbarg, J.-M. Lecomte, C. R. Ganellin, A. Fkyerat, W. Tertiuk, W. Schunack, R. Lipp, H. Stark, K. Purand, PCT Int. Appl. WO 93/14070 (10.01.1992) [Chem. Abstr. 1994, 120, 107004c].
17. J.-C. Schwartz, J.-M. Arrang, M. Garbarg, J.-M. Lecomte, C. R. Ganellin, A. Fkyerat, W. Tertiuk, W. Schunack, R. Lipp, H. Stark, K. Purand, PCT Int. Appl. WO 93/14070 (10.01.1992) [Chem. Abstr. 1994, 120, 107004c].
18. H. Stark, R. Lipp, J.-M. Arrang, M. Garbarg, J.-C. Schwartz, W. Schunack, Eur. J. Med. Chem. 1994, 29, 695-700.
19. H. Stark, R. Lipp, J.-M. Arrang, M. Garbarg, X. Ligneau, J.-C. Schwartz, W. Schunack, Eur. J. Pharm. Sci. 1995, 3, 95-104.
20. X. Ligneau, M. Garbarg, M. L. Vizuete, J. Diaz, K. Purand, H. Stark, W. Schunack, J.-C. Schwartz, J. Pharmacol. Exp. Ther. 1994, 271, 452-459.
21. H. Stark, M. Krause, J.-M. Arrang, X. Ligneau, J.-C. Schwartz, W. Schunack, Bioorg. Med. Chem. Lett. 1994, 4, 2907-2912.
22. E. Schlicker, M. Kathmann, S. Reidemeister, H. Stark, W. Schunack, Br. J. Pharmacol. 1994, 112, 1043-1048, Br. J. Pharmacol. 1994, 113, 657.
23. E. Schlicker, M. Kathmann, S. Reidemeister, H. Stark, W. Schunack, Br. J. Pharmacol. 1994, 112, 1043-1048, Br. J. Pharmacol. 1994, 113, 657.
24. H. Stark, K. Purand, X. Ligneau, A. Rouleau, J.-M. Arrang, M. Garbarg, J.-C. Schwartz, W. Schunack, J. Med. Chem. 1996, 39, 1157-1163.
25. R. Lipp, H. Stark, W. Schunack, in The Histamine Receptor (Eds.: J.-C. Schwartz, H. L. Haas), Ser: Receptor Biochemistry and Methodology, Wiley-Liss., New York, Basel, 1992, Vol. 16, 57-72.
26. M. Garbarg, J.-M. Arrang, A. Rouleau, X. Ligneau, M. Dam Trung Tuong, J.-C. Schwartz, C. R. Ganellin, J. Pharmacol Exp. Ther. 1992, 263, 304-310.
27. J. Hirschfeld, A. Buschauer, S. Elz, W. Schunack, M. Ruat, E. Traiffort, J.-C. Schwartz, J. Med. Chem. 1992, 35, 2231-2238.
28. H. Stark, K. Purand, A. Hüls, X. Ligneau, M. Garbarg, J.-C. Schwartz, W. Schunack, J. Med. Chem. 1996, 39, 1220-1226.
29. C. Sellier, A. Buschauer, S. Elz, W. Schunack, Liebigs Ann. Chem. 1992, 317-323.
30. H. Meerwein, in Methoden der Organischen Chemie (Houben-Weyl) (Eds.: E. Müller, O. Bayer, H. Meerwein, K. Ziegler), Georg Thieme Verlag, Stuttgart, 1965, Vol. VI/3, 24-32.
31. G. W. Gokel, H. J. Durst, Synthesis 1976, 168-184.
32. P. Sieber, B. Riniker, Tetrahedron Lett. 1987, 28, 6031-6034.
33. T. W. Greene, P. G. M. Wuts, in Protective Groups in Organic Synthesis, John Wiley & Sons, New York, 1991, pp. 385-397.
34. R. E. West, A. Zweig, N.-Y. Shin, M. I. Siegel, R. W. Egan, M. A. Clark, Mol. Pharmacol. 1990, 38, 610-613.
35. E. Schlicker, A. Behling, G. Lümmen, M. Göthert, Naunyn-Schmiedebergs Arch. Pharmacol. 1992, 345, 489-493.
36. E. Schlicker, M. Kathmann, H. Bitschau, I. Marr, S. Reidemeister, H. Stark, W. Schunack, Naunyn-Schmiedebergs Arch. Pharmacol. 1996. 353, 482-488.